What happened to Peptide Sciences?
Peptide Sciences, the largest research peptide vendor in the United States by web traffic, voluntarily shut down operations on March 6, 2026. The closure came without advance warning to customers, researchers, or industry partners. The company's website now displays only a brief shutdown notice.
At the time of closure, Peptide Sciences was generating an estimated $7.4 million per month in revenue and receiving approximately 990,000 monthly visits according to third-party traffic analytics. The company had operated for over a decade, building a reputation as one of the most recognized names in the research peptide space. Their catalog included more than 190 research compounds spanning growth hormone secretagogues, metabolic peptides, tissue repair factors, cognitive research compounds, and longevity-related peptides.
The abrupt nature of the shutdown caught the research community off guard. No public statement was issued explaining the decision in detail. Ongoing orders were reportedly canceled, and customer service channels went dark within days. Researchers reported receiving no email notification, no timeline for order fulfillment, and no guidance on refund procedures. Social media and research forums saw an immediate spike in posts from confused customers attempting to contact the company through every available channel.
For researchers who had relied on Peptide Sciences as their primary supplier — many for years — the closure created an immediate supply chain disruption that sent ripples across the research compound market. Academic laboratories with grant-funded projects on fixed timelines were particularly affected, as qualifying a new vendor and validating compound equivalence can take weeks or months.
The timing of the shutdown, coming amid an unprecedented wave of regulatory enforcement against peptide vendors, has led many industry observers to conclude that Peptide Sciences chose to close proactively rather than face potential enforcement action.
Why did Peptide Sciences shut down?
The closure of Peptide Sciences did not happen in a vacuum. It followed a sustained escalation of federal enforcement activity targeting the research peptide and compounding pharmacy industries throughout 2025 and into early 2026. Multiple converging factors created an environment where continued operation carried increasing legal and financial risk.
FDA enforcement escalation. Beginning in September 2025, the FDA issued more than 50 warning letters to peptide vendors, compounding pharmacies, and related businesses. These letters cited violations ranging from unapproved drug distribution to misbranding and manufacturing deficiencies. The pace and volume of enforcement was unprecedented for the peptide sector.
The Amino Asylum warehouse raid. In June 2025, federal agents raided the warehouse operations of Amino Asylum, another prominent research peptide vendor. The raid signaled a shift from warning letters to direct physical enforcement. For vendors across the industry, the raid demonstrated that the FDA was willing to deploy its most aggressive tools against peptide suppliers. This event is widely viewed as a turning point that prompted several vendors to reevaluate their risk exposure.
Resolution of the semaglutide shortage. In February 2025, the FDA officially resolved the semaglutide drug shortage. This resolution eliminated the legal loophole that had allowed compounding pharmacies — and by extension, some research peptide vendors — to produce and sell semaglutide analogs and GLP-1 compounds under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. With the shortage resolved, continued sale of these compounds became significantly riskier from a regulatory standpoint.
The SAFE Drugs Act. Introduced in early 2026, the Strengthening and Advancing Federal Enforcement of Drugs Act proposed expanded authority for the FDA to pursue enforcement actions against entities distributing unapproved peptide products. While the legislation had not yet passed at the time of Peptide Sciences' closure, its introduction signaled bipartisan Congressional support for tighter regulation.
Quality failures and third-party testing. Independent analyses published by Finnrick Analytics and other third-party testing services exposed quality concerns across multiple vendors, including Peptide Sciences. Reports documented retatrutide counterfeits circulating in the market and poor purity scores for CJC-1295 from several suppliers. When third-party testing reveals that products do not meet advertised specifications, it compounds regulatory risk by providing evidence of potential misbranding.
Taken together, these factors created what many industry analysts describe as an untenable operating environment. Rather than wait for a warning letter, inspection, or raid, Peptide Sciences appears to have made the calculation that voluntary closure was preferable to the alternatives.
What does this mean for the research peptide market?
The closure of Peptide Sciences removed the single largest vendor from the research compound market virtually overnight. The approximately 990,000 monthly visits that Peptide Sciences received represent a massive population of researchers, academic institutions, and independent investigators who now need alternative suppliers. The downstream effects are reshaping the market in several significant ways.
Immediate supply disruption. Researchers with active projects faced abrupt supply chain failures. Those in the middle of longitudinal studies or multi-phase research protocols were forced to either pause their work or rapidly qualify new suppliers. Switching vendors mid-study introduces variables around compound purity, synthesis methodology, and batch consistency that can compromise data integrity.
Heightened quality demands. The closure has intensified scrutiny of supplier quality across the board. The third-party testing data that contributed to Peptide Sciences' risk calculus is now being applied more broadly. Researchers are asking harder questions about purity verification, analytical methodology, and whether certificates of analysis represent genuine independent testing or internally generated spec sheets. The Finnrick Analytics findings have made the research community more skeptical of vendor claims generally — and rightly so.
Regulatory momentum. The regulatory environment continues to tighten. RFK Jr. has publicly announced plans for peptide reclassification that could fundamentally alter how research compounds are categorized, sold, and regulated. The direction of travel is clear: the era of minimal oversight for research peptide vendors is ending.
Market consolidation around quality. With the largest vendor gone, the remaining players in the market are absorbing displaced demand. Vendors with robust quality systems, cold-chain logistics, and documented analytical standards are positioned to serve researchers who now prioritize verified integrity over brand familiarity. The bar is higher. That's a good thing.
What should researchers look for in a peptide supplier in 2026?
In the post-Peptide Sciences landscape, researchers evaluating alternative suppliers should apply rigorous criteria before placing orders. The quality failures documented across the industry make due diligence more important than ever.
Third-party Certificate of Analysis with every order — not upon request. A legitimate CoA should accompany every batch as standard documentation. The CoA must be batch-specific — generic CoAs reused across batches are a red flag. Review the CoA for specific batch numbers, testing dates, analyst information, and the identity of the testing laboratory.
HPLC verification and mass spectrometry — both, not one. HPLC quantifies purity; mass spectrometry confirms molecular identity. Both are required for complete compound characterization. Request the actual chromatogram images, not just numerical purity percentages. A supplier that cannot produce the underlying chromatographic data behind their purity claims should not be trusted.
Endotoxin testing. Bacterial endotoxin contamination is a critical quality parameter for research compounds used in cell culture and in vitro assays. Limulus Amebocyte Lysate (LAL) testing detects endotoxin contamination. Suppliers who skip this step are cutting corners on fundamental quality assurance.
Cold-chain shipping — standard, not an upgrade. Peptides are temperature-sensitive molecules that degrade through oxidation, aggregation, and deamidation when exposed to elevated temperatures during transit. A compound that leaves the warehouse at 99% purity can arrive significantly degraded without proper thermal protection. Cold-chain packaging should be the default, not a premium option.
Transparent, documented purity data. Research-grade compounds should meet a minimum purity threshold of 98%, with performance research applications typically requiring 99% or higher. Suppliers should publish their purity standards and provide compound-specific analytical data — not blanket marketing claims.
US-based operations. Domestic operations provide accountability, faster shipping, and clearer regulatory jurisdiction. Direct FDA oversight — while a constraint — provides a layer of structural accountability that offshore suppliers cannot match.
These criteria are not aspirational. They represent the minimum baseline for responsible research compound sourcing in the current regulatory environment.
How is Prove It Performance different?
Prove It Performance was built on a single operating principle: prove it. Not claim it — prove it. With data.
Every compound in the catalog is held to a minimum purity standard of ≥99%, verified by independent third-party analytical laboratories before it ships. The Certificate of Analysis documenting HPLC purity, mass spectrometry identity confirmation, and endotoxin results ships with every order as standard — not available on request, not conditionally included. It comes with the compound.
Endotoxin testing is performed on all compounds. Cold-chain packaging is standard on all shipments. Every scientific claim on product pages links to a PubMed identifier (PMID) so researchers can verify the underlying literature independently. That's the prove-it standard — measurable, traceable, documentable at every step.
For researchers who previously sourced from Peptide Sciences, Prove It Performance carries overlapping compounds including BPC-157, TB500, GHK-CU, Ipamorelin, GLP-1, Sermorelin Acetate, CJC-1295 NO DAC, Epitalon, and NAD+. The full catalog is at Browse all compounds.
The approach is direct: independently verified, high-purity research compounds with complete analytical documentation and proper cold-chain handling on every shipment. In a market where trust has been eroded by quality failures and abrupt closures, the response isn't better marketing. It's better documentation.
What products did Peptide Sciences carry?
Peptide Sciences maintained one of the largest research peptide catalogs in the industry, with over 190 SKUs spanning multiple research categories: growth hormone secretagogues, metabolic research peptides, tissue repair and healing factors, cognitive and neuroprotective compounds, longevity and anti-aging research peptides, antimicrobial peptides, and cosmetic research compounds.
Their growth hormone secretagogue category included ipamorelin, CJC-1295 variants, sermorelin, hexarelin, GHRP-2, and GHRP-6. Metabolic research peptides included GLP-1 receptor agonists, tirzepatide, semaglutide, and related compounds. Tissue repair research compounds included BPC-157, TB-500, and related healing factors used extensively in musculoskeletal and wound repair research models.
Prove It Performance covers many of these same research categories with a curated catalog focused on quality over breadth. While we don't attempt to replicate the full 190+ SKU catalog, the focus on 43 compounds allows for deeper quality control investment per compound — independent third-party testing, endotoxin screening, and cold-chain logistics for every product rather than only select items.
Is Peptide Sciences coming back?
There is no indication that Peptide Sciences plans to resume operations. The company's domain remains active but serves only a static shutdown message — no timeline for reopening, no contact information, no indication the closure is temporary.
Given the regulatory environment that prompted the closure — ongoing FDA enforcement actions, proposed legislation expanding agency authority, and the resolution of drug shortage loopholes — the conditions that would need to change for Peptide Sciences to reopen do not appear imminent.
Researchers should plan for permanent alternatives rather than waiting for a reopening that may never happen. This means qualifying new suppliers now, validating compound quality through independent testing, and establishing backup supply relationships to prevent future single-point-of-failure disruptions.
The broader lesson from the Peptide Sciences closure extends beyond any single vendor. Research supply chains built around a single source — regardless of how established that source may appear — carry inherent risk. A company generating $7.4 million per month in revenue disappeared overnight with no warning. Diversifying suppliers, maintaining rigorous quality verification practices, and staying informed about regulatory developments are the most effective strategies for ensuring uninterrupted access to the research compounds scientific work depends on.
All compounds referenced in this article are research chemicals intended for laboratory and scientific research purposes only. Prove It Performance does not sell products intended for human consumption. Researchers are responsible for ensuring compliance with all applicable local, state, and federal regulations governing the purchase and use of research materials.